Seo Jeong-jin, President of Celltrion, “End of Year Approval Expected for Crown Treatment”



[ad_1]

Celltrion Group Chairman Seo Jeong-jin expressed his expectations for the approval of a new drug for Corona 19 antibody later this year.  Source = YouTube
Celltrion Group Chairman Seo Jeong-jin expressed his expectations for the approval of a new drug for Corona 19 antibody later this year. Source = YouTube


[이코노믹리뷰=황진중 기자] Celltrion Group President Seo Jeong-jin expressed hope that Celltrion (068270) will obtain the license for a new drug for Corona 19 antibodies later this year.

President Seo Jeong-jin said in an interview with MBC Radio’s ‘Kim Jong-bae’s attention’ on the 11th. You can pre-produce the treatment. 100,000 people are enough to treat Korean patients. “

President Seo Jeong-jin added: “To end the coronavirus, a vaccine and a therapeutic agent must be present together.”

Antibody therapy can kill corona virus 19 in the body 4 to 5 days after administration. Chairman Seo said, “Celltrion has developed an antibody treatment (CT-P59), has completed phase 1 and is currently in phases 2 and 3,” said President Suh. “We plan to apply for conditional approval with the Korean Food and Drug Administration in March.”

Celltrion is expected to mass-produce new corona 19 antibody drugs through its own production facility. Chairman Seo explained, “We are cooperating with the Korea Centers for Disease Control and Prevention, the Health Research Institute and the Ministry of Food and Drug Safety, and production has already started.

He said, “In Korea, there are not that many patients, so I think it is enough to have 100,000 people.” “He added.

The reason why the virus must be eliminated within 4 to 5 days after the diagnosis of Corona 19 is that the possibility of becoming a serious patient or with organ damage must be eliminated. President Seo said: “The virus has the highest amount of reproduction between two days before the onset of symptoms and a week after, and exudes toxicity and damages organs. It is a problem to convert, “he said.

President Seo emphasized, “There is no special drug that treats organ damage, and it is difficult to find out in the future. It is more important to diagnose and treat it early.”

Chairman Seo explained: “With Celltrion’s production capacity around 7% worldwide, if we produce as much as possible, we can produce between 1.5 million and 2 million people. It is difficult to produce more than 20 million people even if other countries’ production runs out. ” .

He said: “If we produce about 1.5 million or 2 million people, 100,000 people is enough for domestic use, so we will provide the rest to the desired country.” “The price is not going to be that high.”

[ad_2]